Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology and ophthalmology. For more information, please visit: www.samsungbioepis.com. To see our community guidelines, please visit: bit.ly/2l0yiI3
View Top Employees from Samsung Bioepis| Website | http://www.samsungbioepis.com/ |
| Revenue | $290 million |
| Employees | 756 (546 on RocketReach) |
| Founded | 2012 |
| Phone | +82 32-455-6114 |
| Industry | Pharmaceutical Manufacturing, Manufacturing General, Biotechnology, Manufacturing, Drug Discovery |
| Keywords | Accessible Healthcare |
| Competitors | IDT Biologika, Nanolek, Rentschler Biopharma SE, Therapure Biopharma Inc, Translational Research Institute Australia |
| SIC | SIC Code 80 Companies, SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 5417 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 541711 Companies, NAICS Code 54171 Companies |
Looking for a particular Samsung Bioepis employee's phone or email?
Samsung Bioepis Questions
The Samsung Bioepis annual revenue was $290 million in 2024.
Sang-Jin Pak is the COO of Samsung Bioepis.
546 people are employed at Samsung Bioepis.
Samsung Bioepis is based in Incheon, Incheon.
The NAICS codes for Samsung Bioepis are [5417, 541, 54, 541711, 54171].
The SIC codes for Samsung Bioepis are [80, 283, 28].
Top Samsung Bioepis Employees
-
33
-
13
-
1
-
24
-
11
-
View
Gillian Woollett
Vice President, Head Regulatory Strategy and Policy US at Samsung Bioepis
Washington, DC, US45+ -
ViewKevin Jack
Vice President, Head of EU Manufacturing Operations at Samsung Bioepis
Delft, South Holland, Netherlands2
Related Companies
